Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with poor outcomes with conventional therapy. Nearly 100% of BPDCNs overexpress interleukin 3 receptor subunit alpha (CD123). Given that CD123 is differentially expressed on the surface of BPDCN cells, it has emerg...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Tianyu, Gouble, Agnès, Black, Kathryn L., Skwarska, Anna, Naqvi, Ammar S., Taylor, Deanne, Zhao, Ming, Yuan, Qi, Sugita, Mayumi, Zhang, Qi, Galetto, Roman, Filipe, Stéphanie, Cavazos, Antonio, Han, Lina, Kuruvilla, Vinitha, Ma, Helen, Weng, Connie, Liu, Chang-Gong, Liu, Xiuping, Konoplev, Sergej, Gu, Jun, Tang, Guilin, Su, Xiaoping, Al-Atrash, Gheath, Ciurea, Stefan, Neelapu, Sattva S., Lane, Andrew A., Kantarjian, Hagop, Guzman, Monica L., Pemmaraju, Naveen, Smith, Julianne, Thomas-Tikhonenko, Andrei, Konopleva, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051102/
https://www.ncbi.nlm.nih.gov/pubmed/35484100
http://dx.doi.org/10.1038/s41467-022-29669-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051102/
https://www.ncbi.nlm.nih.gov/pubmed/35484100
http://dx.doi.org/10.1038/s41467-022-29669-8

Ejemplares similares